Parvathi Ranganathan
Overview
Explore the profile of Parvathi Ranganathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown-Burke F, Saadey R, Mao H, Marra P, Brooks E, Wandtke A, et al.
Blood Adv
. 2025 Jan;
PMID: 39825858
Hemophagocytic lymphohistiocytosis (HLH) is a rare but aggressive and potentially lethal hyperinflammatory syndrome characterized by pathologic immune activation and excessive production of proinflammatory cytokines leading to tissue damage and multisystem...
2.
Kumar R, Ranganathan P
J Clin Invest
. 2024 Oct;
134(20).
PMID: 39403925
Expression of tissue-restricted antigens (TRAs) within the thymus is critical for the establishment of self-tolerance; however, exact mechanisms regulating the expression of TRAs has proven more complex than previously appreciated....
3.
Neidemire-Colley L, Khanal S, Braunreiter K, Gao Y, Kumar R, Snyder K, et al.
Blood Adv
. 2024 Jan;
8(4):947-958.
PMID: 38181781
Acute graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic cell transplantation (allo-HCT). Using preclinical mouse models of disease, previous work in our laboratory has linked microRNA-155 (miR-155) to...
4.
Bhatnagar B, Zhao Q, Mims A, Vasu S, Behbehani G, Larkin K, et al.
Leuk Lymphoma
. 2023 Sep;
64(13):2091-2100.
PMID: 37665178
Selinexor, an oral inhibitor of the nuclear transport protein Exportin-1, shows promising single-agent activity in clinical trials of relapsed/refractory (R/R) acute myeloid leukemia (AML) and preclinical synergy with topoisomerase (topo)...
5.
Sircar A, Singh S, Xu-Monette Z, Coyle K, Hilton L, Chavdoula E, et al.
Leukemia
. 2023 Aug;
37(10):2094-2106.
PMID: 37598282
Mantle cell lymphoma (MCL) is a lethal hematological malignancy with a median survival of 4 years. Its lethality is mainly attributed to a limited understanding of clinical tumor progression and...
6.
Goda C, Kolovich S, Rudich A, Karunasiri M, Kulkarni R, Rajgolikar G, et al.
Exp Hematol
. 2023 May;
123:28-33.e3.
PMID: 37209901
Mantle cell lymphoma (MCL) is an aggressive, noncurative, mature B-cell lymphoma, with a median overall survival of 6-7 years. This underlines a need for effective therapeutic strategies to treat MCL...
7.
Neidemire-Colley L, Robert J, Ackaoui A, Dorrance A, Guimond M, Ranganathan P
Front Immunol
. 2023 Jan;
13:1125035.
PMID: 36685565
[This corrects the article DOI: 10.3389/fimmu.2022.1033490.].
8.
Neidemire-Colley L, Robert J, Ackaoui A, Dorrance A, Guimond M, Ranganathan P
Front Immunol
. 2022 Dec;
13:1033490.
PMID: 36505438
To date, the only curative treatment for high-risk or refractory hematologic malignancies non-responsive to standard chemotherapy is allogeneic hematopoietic transplantation (allo-HCT). Acute graft-versus-host disease (GVHD) is a donor T cell-mediated...
9.
Snyder K, Choe H, Gao Y, Sell N, Braunreiter K, Zitzer N, et al.
Front Oncol
. 2021 Nov;
11:760789.
PMID: 34722316
Acute graft--host disease (GVHD) is the leading cause of non-relapse mortality following allogeneic hematopoietic cell transplantation. The majority of patients non-responsive to front line treatment with steroids have an estimated...
10.
Dorrance A, Moutuou M, Goda C, Sell N, Kalyan S, Karunasiri M, et al.
Blood Adv
. 2021 Oct;
6(7):2403-2408.
PMID: 34654057
Acute graft-versus-host disease (aGVHD) is the second most common cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT), underscoring the need for novel therapies. Based on previous work that...